Calendar

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Oncology.

AMCP and Takeda Oncology are pleased to invite you to a PIE webinar on rusfertide, an investigational, first‑in‑class hepcidin mimetic being studied for the treatment of polycythemia vera (PV)—a chronic blood disorder characterized by the overproduction of red blood cells. We’ll review the unmet need, key clinical data, and anticipated product profile, followed by a brief Q&A. We look forward to your participation.

This webinar is offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

A Pre-Approval Information Exchange (PIE) Webinar, presented by Takeda Pharmaceuticals.

Narcolepsy Type 1 (NT1) is a rare, chronic neurologic disorder caused by loss of orexin (hypocretin) neurons and marked by excessive daytime sleepiness and cataplexy. Beyond the classic pentad, additional manifestations can affect many aspects of daily functioning. Existing treatments focus on symptom relief alone, as many treated patients report residual symptoms and ongoing impairment. These limitations underscore the need to investigate therapies that directly target orexin deficiency in NT1.

This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. In order to join this webinar, you must be registered as a user of FormularyDecisions.

This product is in the clinical evaluation stage and has not been approved for use by the FDA. The safety and efficacy of this product have not been established.

An AMCP PA/UM LINK Group Webinar.

How are we doing as an industry as we strive to balance evidence, access, and consistency across coverage policies?   This webinar takes a deep dive into how UM practices vary across payers and how they’ve evolved from 2017–2025. Dr. James D. Chambers, PhD, MPharm, Professor at Tufts Medicine and Center for the Evaluation of Value and Risk in Health, will examine the evidence health plans cite in drug coverage policies and assess how payer criteria align with pivotal clinical trials—using cell and gene therapies as a real‑world case study.

If you haven’t had an opportunity to hear Dr Chambers- you won’t want to miss this!  And if you have, we know you have already registered!  

A Science & Innovation Webinar, presented by Cytokinetics.

• Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is a chronic, progressive condition affecting 1:200 to 1:500 individuals in the US^1,2
• Despite available standard-of-care therapies, patients may experience impaired functional capacity and disease progression, driving the need for therapies that target the underlying oHCM pathophysiology rather than symptoms alone^2-4
• This webinar will be led by Rachel Lavelle, PharmD, who brings complementary clinical and managed care perspectives on oHCM, combining deep experience in cardiology care, guideline-directed therapy implementation, and value-focused cardiovascular outcomes